<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Gen Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J Gen Intern Med</journal-id><journal-id journal-id-type="pmc-domain-id">227</journal-id><journal-id journal-id-type="pmc-domain">jgimed</journal-id><journal-title-group><journal-title>Journal of General Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0884-8734</issn><issn pub-type="epub">1525-1497</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10853089</article-id><article-id pub-id-type="pmcid-ver">PMC10853089.1</article-id><article-id pub-id-type="pmcaid">10853089</article-id><article-id pub-id-type="pmcaiid">10853089</article-id><article-id pub-id-type="pmid">37653209</article-id><article-id pub-id-type="doi">10.1007/s11606-023-08385-z</article-id><article-id pub-id-type="publisher-id">8385</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research: Qualitative Research</subject></subj-group></article-categories><title-group><article-title>Examining Adult Patients&#8217; Success with Discontinuing Long-term Benzodiazepine Use: a Qualitative Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7039-3618</contrib-id><name name-style="western"><surname>Takamine</surname><given-names initials="L">Linda</given-names></name><degrees>PhD</degrees><address><email>linda.takamine@va.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krein</surname><given-names initials="SL">Sarah L.</given-names></name><degrees>PhD, RN</degrees><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ratliff</surname><given-names initials="E">Erika</given-names></name><degrees>MSW</degrees><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Strominger</surname><given-names initials="J">Julie</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Virk</surname><given-names initials="A">Amarra</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maust</surname><given-names initials="DT">Donovan T.</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.413800.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0419 7525</institution-id><institution>VA Center for Clinical Management Research, </institution><institution>VA Ann Arbor Healthcare System, </institution></institution-wrap>2215 Fuller Road, Mail Stop 152, Ann Arbor, MI USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jmfr291</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7347</institution-id><institution>Institute for Healthcare Policy and Innovation, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jmfr291</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7347</institution-id><institution>Department of Internal Medicine, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jmfr291</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7347</institution-id><institution>Department of Psychiatry, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/032db5x82</institution-id><institution-id institution-id-type="GRID">grid.170693.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2353 285X</institution-id><institution>Department of Psychiatry and Behavioral Neurosciences, </institution><institution>University of South Florida, </institution></institution-wrap>Tampa, FL USA </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2024</year></pub-date><volume>39</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">455535</issue-id><fpage>247</fpage><lpage>254</lpage><history><date date-type="received"><day>25</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-01 00:25:38.220"><day>01</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11606_2023_Article_8385.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Little is known about patients&#8217; experiences with benzodiazepine (BZD) discontinuation, which is thought to be challenging given the physiological and psychological dependence and accompanying potential for significant withdrawal symptoms. The marked decline in BZD prescribing over the past decade in the US Department of Veterans Affairs healthcare system presents an important opportunity to examine the experience of BZD discontinuation among long-term users.</p></sec><sec><title>Objective</title><p id="Par2">Examine the experience of BZD discontinuation among individuals prescribed long-term BZD treatment to identify factors that contributed to successful discontinuation.</p></sec><sec><title>Design</title><p id="Par3">Descriptive qualitative analysis of semi-structured interviews conducted between April and December of 2020.</p></sec><sec><title>Participants</title><p id="Par4">A total of 21 Veterans who had been prescribed long-term BZD pharmacotherapy (i.e.,&#8201;&gt;&#8201;120&#160;days of exposure in a 12-month period) and had their BZD discontinued.</p></sec><sec><title>Approach</title><p id="Par5">We conducted semi-structured interviews with Veteran participants to learn about their BZD use and the process of discontinuation, with interviews recorded and transcribed verbatim. Data were deductively and inductively coded and coded text entered into a matrix to identify factors that contributed to successful BZD discontinuation.</p></sec><sec><title>Key Results</title><p id="Par6">The mean age of interview participants was 63.0&#160;years (standard deviation 3.9); 94.2% were male and 76.2% were white. Of 21 participants, only 1 had resumed BZD treatment (prescribed by a non-VA clinician). Three main factors influenced success with discontinuation: (1) participants&#8217; attitudes toward BZDs (e.g., risks of long-term use, perceived lack of efficacy, potential for dependence); (2) limited withdrawal symptoms; and (3) effective alternatives, either from their clinician (e.g., medication, psychotherapy) or identified by participants.</p></sec><sec><title>Conclusions</title><p id="Par7">BZD discontinuation after long-term use is relatively well tolerated, and participants appreciated reducing their medication exposure, particularly to one associated with physical dependence. These findings may help reduce both patient and clinician anxiety related to BZD discontinuation.</p></sec><sec><title>Supplementary Information:</title><p>The online version contains supplementary material available at 10.1007/s11606-023-08385-z.</p></sec></abstract><kwd-group xml:lang="en"><title>KEY WORDS</title><kwd>benzodiazepine</kwd><kwd>discontinuation</kwd><kwd>qualitative</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000738</institution-id><institution>U.S. Department of Veterans Affairs</institution></institution-wrap></funding-source><award-id>I01HX002340</award-id><principal-award-recipient><name name-style="western"><surname>Maust</surname><given-names>Donovan T.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Society of General Internal Medicine 2024</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>